Business Description

Eli Lilly & Co. is involved in developing, manufacturing, and selling pharmaceutical products. Products include Diabetes, Neuroscience, Immunology, and Neuroscience. Baqsimi and Basaglar are Diabetes products. Alimta and Cyramza are Oncology products. Olumiant and Taltz the Immunology product. Cymbalta and Emgality are Neuroscience products. Review and Zyprexa are Neuroscience products. Bamlanivimab and Cialis are the other therapies. Forteo is another. Eli Lilly founded the company in May 1876. It is located in Indianapolis, IN.

Key Financials

Revenue (US$ Mn)

• US$ 28,318 Mn was Eli Lilly & Co’s annual revenue in 2021, a 15.4% increase from 2020 figures
• Eli Lilly & Co indexed a 9.95% increase in annual revenues from 2019, amounting to US$ 24,540 Mn in 2020
• Eli Lilly & Co generated total revenue of US$ 22,320 Mn in 2019
• Annual revenue of US$ 24,556 Mn was indexed by Microsoft Corporation in 2018

Operating Income (US$ Mn)

• US$ 7,548 Mn was the operating income generated by Eli Lilly & Co in 2021
• Eli Lilly & Co’s operating income for 2020 was US$ 7,230 Mn, a 37.3% increase from 2019
• From 2018’s operating incomes, Eli Lilly & Co registered a 38.73% increase in 2019, amounting to US$ 5,266 Mn
• An operating income of US$ 3,796 Mn was generated in 2018 by Eli Lilly & Co

Net Income (US$ Mn)

• Eli Lilly & Co’s net income for 2021 was US$ 5,581 Mn, a -9.89% decrease from 2020
• The net income generated by Eli Lilly & Co in 2020 was US$ 6,194 Mn
• At a 157.38% increase, Eli Lilly & Co’s net income of US$ 8,318 Mn was indexed in 2019
• Eli Lilly & Co generated a net income of US$ 3,232 Mn in 2018

Operating Margin %

• 27% was Eli Lilly & Co’s operating margin in 2021, a -9.49% decrease from 2020 figures
• Eli Lilly & Co indexed a 25% increase in operating margins from 2019, amounting to 30% in 2020
• Eli Lilly & Co generated an operating margin of 24% in 2019
• An operating margin of 16% was indexed by Microsoft Corporation in 2018

Gross Margin %

• 74% was the gross margin generated by Eli Lilly & Co in 2021
• Eli Lilly & Co’s gross margin for 2020 was 78%, a -1.4% decrease from 2019
• From 2018’s gross margins, Eli Lilly & Co registered a 6.78% increase in 2019, amounting to 79%
• A gross margin of 74% was generated in 2018 by Eli Lilly & Co

SWOT Analysis

Strengths

Revenue performance

The revenue performance of the company improved in FY2020, which enables it to provide higher returns to its shareholders and attract further investments. Revenue growth enhances the company’s ability to allocate adequate funds for growth and expansion. In FY2020, Eli Lilly reported revenue of US$24,539.8 million as compared to US$22,319.5 million in FY2019, which indicates an annual growth of 9.9%. The revenue growth was due to an increase in revenue from Diabetes, Oncology, Immunology, Neuroscience, and Other product categories by 6.3%, 15.3%, 37.3%, 6.3%, and 1.2%, respectively. In FY2020, the company’s operating margin was 24.7% as compared to 22.5% in FY2019. Improving operating performance indicates the company’s focus on efficient cost management.

Get this premium content

The Premium data is Locked

Buy Now to Unlock Premium Data

Request Sample Data